Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04964037
Status:
COMPLETED
Last Update Posted:
2021-07-15
First Post:
2021-06-29
Brief Title:
Analysis of Relationship Between Metabolic Biomarkers and Efficacy of Glucocorticoid in AECOPD
Sponsor:
Peking University Third Hospital
Organization:
Peking University Third Hospital
Study Overview
Official Title:
Analysis of Relationship Between Metabolic Biomarkers and Efficacy of Systemic Glucocorticoid in Acute Exacerbation of COPD
Status:
COMPLETED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evidences have shown that systemic glucocorticoid cannot not be benefit to all of the patients with AECOPD The problem that how the clinicians can screen the patients who can benefit from systemic glucocorticoid needs to be solved Our previous study found that serum metabolites profile in COPD patients differed from that in controls Therefore we hypothesized that metabolome changes in patients with AECOPD may be associated with the efficacy of systemic glucocorticoid In this study we will utilize ultraperformance liquid chromatography mass spectrometry LC-MS and gas chromatography mass spectrometry GC-MS methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure We aim to detect the metabolic biomarkers and metabolic pathways which are related to efficacy of systemic glucocorticoid and contribute to the precise treatment of COPD
Detailed Description:
Acute exacerbation of chronic obstructive pulmonary disease AECOPD significantly increases the mortality of the patients with COPD Guidelines have recommended systemic glucocorticoid as regular treatment Recently evidences have shown that systemic glucocorticoid cannot not be benefit to all of the patients with AECOPD Thus the problem that how the clinicians can screen the patients who can benefit from systemic glucocorticoid needs to be solved urgently A previous study found that plasma metabolome changed significantly after dexamethasone treatment in health participants Furthermore inter-person variability was high and remained uninfluenced by treatment suggesting the potential of metabolomics for predicting the efficacy and side effects of systemic glucocorticoid Our previous study found that serum metabolites profile in COPD patients differed from that in controls Therefore we hypothesized that metabolome changes in patients with AECOPD may be associated with the efficacy of systemic glucocorticoid In this study we will utilize ultraperformance liquid chromatography mass spectrometry LC-MS and gas chromatography mass spectrometry GC-MS methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure We aim to detect the metabolic biomarkers and metabolic pathways which are related to efficacy of systemic glucocorticoid and contribute to the precise treatment of COPD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None